Among the EGFR-1-negative cases, six out of 58 (10.3%) expressed HER-2, whereas the HER-2-expressing tumours accounted for eight of the 29 EGFR-1-positive cases (27.6%). The gene discussed is ERBB2; the disease is neoplasm.